BidaskClub upgraded shares of AVEO Pharmaceuticals (NASDAQ:AVEO) from a buy rating to a strong-buy rating in a research report released on Tuesday.

Separately, HC Wainwright assumed coverage on shares of AVEO Pharmaceuticals in a research note on Thursday, August 16th. They set a buy rating and a $6.50 price objective for the company. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of Buy and an average price target of $5.50.

Shares of NASDAQ AVEO opened at $2.68 on Tuesday. AVEO Pharmaceuticals has a 12-month low of $1.86 and a 12-month high of $4.15. The stock has a market cap of $336.86 million, a P/E ratio of -16.57 and a beta of 1.64. The company has a debt-to-equity ratio of -0.36, a current ratio of 1.16 and a quick ratio of 1.16.

AVEO Pharmaceuticals (NASDAQ:AVEO) last announced its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.09). The company had revenue of $0.43 million for the quarter, compared to the consensus estimate of $1.35 million. equities analysts forecast that AVEO Pharmaceuticals will post -0.26 earnings per share for the current year.

In other news, major shareholder Equity Opportunities Iv Growth purchased 663,716 shares of the company’s stock in a transaction dated Tuesday, August 21st. The stock was acquired at an average price of $2.26 per share, with a total value of $1,499,998.16. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. In the last three months, insiders bought 919,611 shares of company stock valued at $2,002,558. Corporate insiders own 4.40% of the company’s stock.

Several institutional investors have recently bought and sold shares of AVEO. BlackRock Inc. grew its stake in shares of AVEO Pharmaceuticals by 271.9% in the 2nd quarter. BlackRock Inc. now owns 6,977,746 shares of the biopharmaceutical company’s stock valued at $15,770,000 after buying an additional 5,101,281 shares during the period. NEA Management Company LLC grew its stake in shares of AVEO Pharmaceuticals by 8.7% in the 2nd quarter. NEA Management Company LLC now owns 17,783,722 shares of the biopharmaceutical company’s stock valued at $40,091,000 after buying an additional 1,421,028 shares during the period. Point72 Asset Management L.P. grew its stake in shares of AVEO Pharmaceuticals by 213.5% in the 1st quarter. Point72 Asset Management L.P. now owns 940,403 shares of the biopharmaceutical company’s stock valued at $2,727,000 after buying an additional 640,403 shares during the period. Tibra Equities Europe Ltd purchased a new stake in shares of AVEO Pharmaceuticals in the 1st quarter valued at approximately $750,000. Finally, Bank of New York Mellon Corp grew its stake in shares of AVEO Pharmaceuticals by 279.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 288,073 shares of the biopharmaceutical company’s stock valued at $651,000 after buying an additional 212,059 shares during the period. 50.75% of the stock is owned by institutional investors and hedge funds.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Featured Story: Technical Analysis

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.